Skip to Content
IRS Whistleblowers, click here to contact the Ways & Means Committee about waste, fraud, and abuse.

What They’re Saying: Stakeholders Praise Medical Innovation Legislation from Ways & Means Republicans

April 19, 2022 — Blog    — Health    — Select Revenue Measures    — Trade   

Ways & Means Republicans have unveiled legislation to secure medical supplies and support innovation for a healthier future. Stakeholders are praising the effort as a path forward to improve American health care. The legislation includes bills led by Rep. Vern Buchanan (R-FL), Leader of the Subcommittee on Health, Rep. Mike Kelly (R-PA), Leader of the Subcommittee on Select Revenue Measures, Rep. Drew Ferguson (R-GA), and Rep. Brad Wenstrup (R-OH), which ensure a healthier future for all Americans.

The Securing America’s Medicines and Supply (SAMS) Coalition:

“Our country needs a robust domestic infrastructure for life-saving therapies and supplies – from complex biologics, biosimilars, and generics to critical personal protective equipment (PPE) and devices. We support tax law that promotes increased manufacturing operations within the United States. The American-Made Medicine Act recognizes the hard-work of U.S. manufacturers. ”

National Venture Capital Association, TechNet and the Center for American Entrepreneurship (CAE) in a joint statement:

“By making long-term investment in innovation more attractive, this package of proposals will pay enormous dividends for our economy and improve America’s long-term competitiveness. We thank Representatives Brady, Buchanan, Kelly, and Wenstrup for their leadership and look forward to continuing to work with policymakers to pass these solutions into law.”

Biotechnology Innovation Organization (BIO):

“A Ways & Means package led by Health Subcommittee Ranking Member Vern Buchanan, Rep. Brad Wenstrup, DPM, Rep. Drew Ferguson, DDS, and Rep. Mike Kelly is a critical building block for future biotech innovation. By providing much-needed incentives for research, development, novel manufacturing, and more, it will allow biotech companies — especially small startups – to do what they do best: solve the world’s most complex scientific challenges.”